Skip to Content

Ovid Therapeutics Inc OVID

Morningstar Rating
$3.23 +0.02 (0.62%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

OVID is trading at a 44% discount.
Price
$3.21
Fair Value
$2.56
Uncertainty
Extreme
1-Star Price
$56.57
5-Star Price
$7.21
Economic Moat
Jbkv
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OVID is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.21
Day Range
$3.173.29
52-Week Range
$2.574.14
Bid/Ask
$3.06 / $3.23
Market Cap
$228.39 Mil
Volume/Avg
176,642 / 212,979

Key Statistics

Price/Earnings (Normalized)
Price/Sales
578.38
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
40

Comparables

Valuation

Metric
OVID
PLRX
CBAY
Price/Earnings (Normalized)
Price/Book Value
2.581.6312.65
Price/Sales
578.38477.92111.01
Price/Cash Flow
Price/Earnings
OVID
PLRX
CBAY

Financial Strength

Metric
OVID
PLRX
CBAY
Quick Ratio
9.2217.4310.70
Current Ratio
9.5517.7210.96
Interest Coverage
−145.34−5.27
Quick Ratio
OVID
PLRX
CBAY

Profitability

Metric
OVID
PLRX
CBAY
Return on Assets (Normalized)
−33.42%−22.68%−30.06%
Return on Equity (Normalized)
−42.55%−24.50%−51.97%
Return on Invested Capital (Normalized)
−40.93%−28.46%−30.87%
Return on Assets
OVID
PLRX
CBAY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRKxgcwwddBfvc$550.4 Bil
VRTX
Vertex Pharmaceuticals IncMrnrynjpJrqtrns$101.7 Bil
REGN
Regeneron Pharmaceuticals IncRdpzllsdPkpyjq$98.1 Bil
MRNA
Moderna IncWdysqkgWjqm$39.1 Bil
ARGX
argenx SE ADRZvsypmgbzDpvp$21.7 Bil
BNTX
BioNTech SE ADRRvqgwsqhlZysp$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncJqmlshhMtlnlmk$18.4 Bil
BMRN
Biomarin Pharmaceutical IncFysglfgmRyvmcz$17.1 Bil
RPRX
Royalty Pharma PLC Class AXqhkbcrrtWptqc$12.5 Bil
INCY
Incyte CorpZrvlvwfnDfcsgt$11.9 Bil

Sponsor Center